Thermo Fisher Scientific Inc (TMO) concluded trading on Thursday at a closing price of $606.74, with 3.35 million shares of worth about $2.03 billion changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -1.35% during that period and on January 30, 2025 the price saw a gain of about 6.78%. Currently the company’s common shares owned by public are about 382.50M shares, out of which, 381.96M shares are available for trading.
Stock saw a price change of 5.55% in past 5 days and over the past one month there was a price change of 15.33%. Year-to-date (YTD), TMO shares are showing a performance of 16.63% which increased to 8.78% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $493.30 but also hit the highest price of $627.88 during that period. The average intraday trading volume for Thermo Fisher Scientific Inc shares is 1.96 million. The stock is currently trading 8.63% above its 20-day simple moving average (SMA20), while that difference is up 12.95% for SMA50 and it goes to 6.39% higher than SMA200.
Thermo Fisher Scientific Inc (NYSE: TMO) currently have 382.50M outstanding shares and institutions hold larger chunk of about 89.85% of that.
The stock has a current market capitalization of $232.08B and its 3Y-monthly beta is at 0.77. PE ratio of stock for trailing 12 months is 36.72, while it has posted earnings per share of $16.52 in the same period. Its PEG reads 3.73 and has Quick Ratio of 1.29 while making debt-to-equity ratio of 0.63. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TMO, volatility over the week remained 2.28% while standing at 2.31% over the month.
Stock’s fiscal year EPS is expected to rise by 6.28% while it is estimated to increase by 10.83% in next year. EPS is likely to shrink at an annualized rate of 9.84% for next 5-years, compared to annual growth of 12.50% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Bernstein on January 10, 2025 offering an Outperform rating for the stock and assigned a target price of $630 to it. On October 14, 2024, Redburn Atlantic Initiated their recommendations, while on October 01, 2024, Stephens Initiated their ratings for the stock with a price target of $680. Stock get an Overweight rating from Wells Fargo on August 28, 2024.
